Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems
Acquisition Complements
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240206814523/en/
Fast and highest sensitivity SII Lago X in vivo imaging with capacity for 10 animals simultaneously (Photo: Business Wire)
Established in 2009 in
The SII flagship system Lago X is designed for superior sensitivity and high-volume in-vivo imaging research. The SII high-efficiency AMI HTX system permits BLI, FLI and X-ray imaging with a benchtop system. SII Aura software provides a seamless workflow for enhanced productivity.
“Spectral Instruments Imaging systems perfectly complement the Bruker Preclinical offering,” said
Dr.
Financial details of the transaction were not disclosed. In 2023, SII generated revenues of over
About
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206814523/en/
Investor Contact:
Sr. Director, Investor Relations & Corporate Development
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Media Contact:
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com
Source: